SAWAI GROUP HOLDINGS Co., Ltd. Logo

SAWAI GROUP HOLDINGS Co., Ltd.

A leading Japanese generic drug maker expanding into digital health and wellness solutions.

4887 | T

Overview

Corporate Details

ISIN(s):
JP3323040000
LEI:
Country:
Japan
Address:
大阪市淀川区宮原5丁目2−30
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Sawai Group Holdings Co., Ltd. is a holding company primarily engaged in the pharmaceutical business. Its core subsidiary, Sawai Pharmaceutical Co., Ltd., is a leading Japanese manufacturer of generic drugs, focusing on the research, development, production, and sale of high-quality, affordable medications across various therapeutic areas, including treatments for hypertension and dyslipidemia. The Group aims to contribute to reducing patient financial burdens and supporting sustainable healthcare systems. In addition to its core generics business, the company is expanding into the broader healthcare field, including digital health solutions and wellness services through subsidiaries such as FrontAct, which develops treatment support apps and provides health monitoring devices. The Group's mission is to support healthier lives for people worldwide.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-10-31 03:04
Registration Form
訂正発行登録書
Japanese 24.2 KB
2025-06-27 02:47
Regulatory News Service
訂正発行登録書
Japanese 10.0 KB
2025-06-26 07:49
Post-Annual General Meeting Information
臨時報告書
Japanese 31.2 KB
2025-06-24 08:06
Governance Information
内部統制報告書-第4期(2024/04/01-2025/03/31)
Japanese 24.3 KB
2025-06-24 08:06
Registration Form
確認書
Japanese 9.0 KB
2025-06-24 08:05
Annual Report
有価証券報告書-第4期(2024/04/01-2025/03/31)
Japanese 2.0 MB
2025-05-27 05:40
Registration Form
訂正発行登録書
Japanese 9.6 KB
2025-05-27 02:50
Regulatory News Service
臨時報告書
Japanese 20.1 KB
2025-04-03 06:28
Transaction in Own Shares
自己株券買付状況報告書(法24条の6第1項に基づくもの)
Japanese 23.4 KB
2025-03-05 07:02
Transaction in Own Shares
自己株券買付状況報告書(法24条の6第1項に基づくもの)
Japanese 27.8 KB
2025-02-05 07:08
Transaction in Own Shares
自己株券買付状況報告書(法24条の6第1項に基づくもの)
Japanese 28.2 KB
2025-01-08 07:53
Transaction in Own Shares
自己株券買付状況報告書(法24条の6第1項に基づくもの)
Japanese 27.7 KB
2024-12-04 07:05
Transaction in Own Shares
自己株券買付状況報告書(法24条の6第1項に基づくもの)
Japanese 28.5 KB
2024-11-11 07:47
Interim Report
確認書
Japanese 9.1 KB
2024-11-11 07:46
Interim Report
半期報告書-第4期(2024/04/01-2025/03/31)
Japanese 350.6 KB

Automate Your Workflow. Get a real-time feed of all SAWAI GROUP HOLDINGS Co., Ltd. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for SAWAI GROUP HOLDINGS Co., Ltd.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for SAWAI GROUP HOLDINGS Co., Ltd. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Oncopeptides Logo
Develops targeted therapies for hematological cancers using peptide-drug conjugate technology.
Sweden
ONCO
Onesano S.A. Logo
Develops patented nutritional products for humans, animals, and agriculture.
Poland
SKT
OnKure Therapeutics, Inc. Logo
Developing less toxic, tumor-agnostic kinase inhibitors for precision cancer therapy.
United States of America
OKUR
ONO PHARMACEUTICAL CO., LTD. Logo
Develops innovative medicines for high unmet needs in oncology, immunology, and neurology.
Japan
4528
OPKO Health Inc. Logo
Provides clinical diagnostics & develops novel therapies for serious & pediatric diseases.
Israel
OPK
OPKO HEALTH, INC. Logo
A biopharma and diagnostics firm offering novel therapies and full-service clinical lab testing.
United States of America
OPK
Opthea Ltd Logo
Biopharma that discontinued its wet AMD therapy after its lead drug failed Phase 3 trials.
United States of America
OPT
OPTUS Pharmaceutical Co., Ltd. Logo
Develops and manufactures ophthalmic solutions for dry eye, infections, and inflammation.
South Korea
131030
Opus Genetics, Inc. Logo
Developing gene therapies for inherited retinal diseases and other blinding conditions.
United States of America
IRD
ORAGENICS INC Logo
Biotech developing intranasal drugs for concussion and other brain disorders.
United States of America
OGEN

Talk to a Data Expert

Have a question? We'll get back to you promptly.